

08:30-09:00	Registration, welcome and opening					
09:00-09:10	Mélanie Prague & Jérémie Guedj					
	Few words of introduction					
	odeling to support vaccine development Chair: Alan Perelson					
09:10-09:40	Rodolphe Thiébaut, Université Bordeaux					
	Modelling B cell response to vaccine. Exemple of Ad26/MVA against Ebola virus disease					
09:40-10:00	Nicolas Ratto, Nova Discovery					
10 10 10 00	A multi-strain model of immunization against IAV viruses after infection or vaccination					
10:10-10:30	Marie Alexandre, INRIA					
10:30-11:00	Modeling viral and humoral dynamics after vaccination against SARS-CoV-2 in NHPs					
	Coffee break					
11:00-11:30	ssion 2: Models of SARS-CoV-2 infection and treatment Chair: Mélanie Prague 00-11:30 Alan Perelson, Los Alamos National Laboratory					
11.00-11.30	Modeling SARS-CoV-2 Drug Resistance and Paxlovid Viral Rebound					
11:30-11:50	Stanca Ciupe, Virginia Tech					
11.50-11.50	Modeling within-host and aerosol dynamics of SARS-CoV-2					
11:50-12:10	Aurélien Marc, INSERM					
	Using NHPs to characterize the impact of variants of concern on viral dynamics					
12:10-12:30	Joseph Standing, University College London					
	Comparative assessment of SARS-CoV-2 viral dynamic models to inform					
	pharmacodynamic model development in early treatment trials					
12:30-13:30	Lunch					
Session 3: Multiscale models Chair: Samuel Alizon						
13:30-14:00	Lulla Opatowski, Institut Pasteur					
	What can we expect to learn from multiscale models?					
14:00-14:20	Hind Zaaraoui, INSERM					
44.00.44.40	Impact of antiviral treatment on household transmission					
14:20-14:40	Alexander Kulesza, Nova Discovery					
	Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions					
14:40-15:00	Light coffee break					
	sion 4: Chronic infections. Chair: Jérémie Guedj					
15:00-15:30	Baptiste Elie, CNRS					
10.00 10.00	A cohort study to describe and model HPV kinetics					
15:30-15:50	Laura Liao, Merck					
	Mechanistic Immune-Viral Dynamics Modeling Platform for HIV Cure Drug Development					
15:50-16:10	Selma El Messaoudi, INSERM					
	Dynamics of HBV markers during long-term treatment with lamivudine and peg-IFN					
16:10-16:25	Break					
Session 5: Acute infections Chair: Lulla Opatowski						
16:25-16:25	Withdraw					
16:25-16:45	Samuel Alizon, CNRS					
10.20	Within-Host Stochastic Emergence Dynamics of Immune-Escape Mutants					
16:45-17:05	Joshua Weitz, Georgia Tech					
10.40 17.00	Modeling synergistic dynamics in phage therapy					
5min Wrap-u						
Jillili Wiap-u	y					